Indivior PLC (INDV) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.612x

Based on the latest financial reports, Indivior PLC (INDV) has a cash flow conversion efficiency ratio of -0.612x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX158.00 Million ≈ $19.22K USD) by net assets (GBX-258.00 Million ≈ $-31.39K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Indivior PLC net asset quality index to measure how much of total assets are equity-financed.

Indivior PLC - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Indivior PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INDV cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Indivior PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Indivior PLC ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
VIRINCHI ORD (BSE)
NSE:VIRINCHI
0.014x
Smithson Investment Trust PLC
LSE:SSON
0.000x
Vaswani Industries Limited
NSE:VASWANI
0.072x
Fredonia Mining Inc
V:FRED
0.640x
Initiator Pharma A/S
ST:INIT
-0.144x
FACILITIES BY ADF LS-01
F:ZC8
N/A
Assura PLC
LSE:AGR
0.042x
Marti Otel Isletmeleri AS
IS:MARTI
-0.004x

Annual Cash Flow Conversion Efficiency for Indivior PLC (2011–2024)

The table below shows the annual cash flow conversion efficiency of Indivior PLC from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Indivior PLC worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 GBX-348.00 Million
≈ $-42.34K
GBX36.00 Million
≈ $4.38K
-0.103x -100.36%
2023-12-31 GBX-11.00 Million
≈ $-1.34K
GBX-315.00 Million
≈ $-38.33K
28.636x +36611.36%
2022-12-31 GBX51.00 Million
≈ $6.21K
GBX-4.00 Million
≈ $-486.68
-0.078x -104.51%
2021-12-31 GBX203.00 Million
≈ $24.70K
GBX353.00 Million
≈ $42.95K
1.739x +173.88%
2020-12-31 GBX82.00 Million
≈ $9.98K
GBX-193.00 Million
≈ $-23.48K
-2.354x -425.77%
2019-12-31 GBX209.00 Million
≈ $25.43K
GBX151.00 Million
≈ $18.37K
0.722x -84.26%
2018-12-31 GBX66.00 Million
≈ $8.03K
GBX303.00 Million
≈ $36.87K
4.591x +415.92%
2017-12-31 GBX-203.00 Million
≈ $-24.70K
GBX295.00 Million
≈ $35.89K
-1.453x -5.33%
2016-12-31 GBX-295.00 Million
≈ $-35.89K
GBX407.00 Million
≈ $49.52K
-1.380x -20.29%
2015-12-31 GBX-279.00 Million
≈ $-33.95K
GBX320.00 Million
≈ $38.93K
-1.147x -23.82%
2014-12-31 GBX-475.00 Million
≈ $-57.79K
GBX440.00 Million
≈ $53.54K
-0.926x +92.27%
2013-12-31 GBX-66.00 Million
≈ $-8.03K
GBX791.00 Million
≈ $96.24K
-11.985x -300.67%
2012-12-31 GBX145.00 Million
≈ $17.64K
GBX866.00 Million
≈ $105.37K
5.972x +112.17%
2011-12-31 GBX254.00 Million
≈ $30.90K
GBX715.00 Million
≈ $86.99K
2.815x --

About Indivior PLC

LSE:INDV UK Drug Manufacturers - Specialty & Generic
Market Cap
$18.79 Million
GBX154.47 Billion GBX
Market Cap Rank
#25317 Global
#266 in UK
Share Price
GBX1238.00
Change (1 day)
+0.00%
52-Week Range
GBX1238.00 - GBX1238.00
All Time High
GBX2481.00
About

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more